Arbaclofen in fragile X syndrome: results of phase 3 trials

被引：0
作者：
Elizabeth Berry-Kravis
Randi Hagerman
Jeannie Visootsak
Dejan Budimirovic
Walter E. Kaufmann
Maryann Cherubini
Peter Zarevics
Karen Walton-Bowen
Paul Wang
Mark F. Bear
Randall L. Carpenter
机构：
[1] Rush University Medical Center,Departments of Pediatrics, Neurological Sciences, Biochemistry
[2] University of California Davis Medical Center,MIND Institute and Department of Pediatrics
[3] Emory University,Department of Human Genetics
[4] Kennedy Krieger Institute,Departments of Psychiatry &Behavioral Sciences
[5] the Johns Hopkins Medical Institutions,Department of Neurology, Boston Children’s Hospital
[6] Boston,undefined
[7] MA 02115 and Greenwood Genetic Center,undefined
[8] Seaside Therapeutics Inc,undefined
[9] Simons Foundation Autism Research Initiative,undefined
[10] Autism Speaks,undefined
[11] The Picower Institute for Learning and Memory,undefined
[12] Massachusetts Institute of Technology,undefined
[13] Rett Syndrome Research Trust,undefined
来源：
Journal of Neurodevelopmental Disorders | 2017年 / 9卷
关键词：
Fragile X syndrome; Arbaclofen; GABA agonist; FMR1; Targeted treatment; Neurodevelopmental disorder;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Fragile X Syndrome
    Donnenfeld A.E.
    The Indian Journal of Pediatrics, 1998, 65 (4) : 513 - 518
  • [42] Fragile X Syndrome
    McLennan, Yingratana
    Polussa, Jonathan
    Tassone, Flora
    Hagerman, Randi
    CURRENT GENOMICS, 2011, 12 (03) : 216 - 224
  • [43] Fragile X syndrome
    Terracciano, A
    Chiurazzi, P
    Neri, G
    AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS, 2005, 137C (01) : 32 - 37
  • [44] Fragile X syndrome
    Hagerman, Randi J.
    Berry-Kravis, Elizabeth
    Hazlett, Heather Cody
    Bailey, Donald B., Jr.
    Moine, Herve
    Kooy, R. Frank
    Tassone, Flora
    Gantois, Ilse
    Sonenberg, Nahum
    Mandel, Jean Louis
    Hagerman, Paul J.
    NATURE REVIEWS DISEASE PRIMERS, 2017, 3
  • [45] Fragile X Syndrome
    Schwarte, Andrea R.
    SCHOOL PSYCHOLOGY QUARTERLY, 2008, 23 (02) : 290 - 300
  • [46] A Comprehensive Review of Fragile X Syndrome and Fragile X Premutation Associated Conditions in Africa
    Mbachu, Chioma N. P.
    Mbachu, Ikechukwu Innocent
    Hagerman, Randi
    GENES, 2024, 15 (06)
  • [47] Phase II and III drugs for the treatment of fragile X syndrome
    Politte, Laura C.
    McDougle, Christopher J.
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (01): : 47 - 65
  • [48] Updated report on tools to measure outcomes of clinical trials in fragile X syndrome
    Budimirovic, Dejan B.
    Berry-Kravis, Elizabeth
    Erickson, Craig A.
    Hall, Scott S.
    Hessl, David
    Reiss, Allan L.
    King, Margaret K.
    Abbeduto, Leonard
    Kaufmann, Walter E.
    JOURNAL OF NEURODEVELOPMENTAL DISORDERS, 2017, 9
  • [49] Fragile X syndrome clinical trials: exploring parental decision-making
    D'Amanda, C. S.
    Peay, H. L.
    Wheeler, A. C.
    Turbitt, E.
    Biesecker, B. B.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2019, 63 (08) : 926 - 935
  • [50] Facilitating individuals and families affected by fragile X syndrome to participate in medication trials
    Eley, S. E. A.
    McKechanie, A. G.
    Campbell, S.
    Stanfield, A. C.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2020, 64 (11) : 864 - 874
12345